SAB Biotherapeutics, Inc. (SABS)

Over the past six months, SAB Biotherapeutics, Inc.'s stock has been volatile, with a 52-week range between $1.05 and $6.60. In March 2026, the company announced and closed an $85 million public offering to fund the development of SAB-142. The company reported its full-year 2025 financial results and business highlights, including progress on the Phase 2b SAFEGUARD study for SAB-142. In July 2025, SAB BIO raised $175 million in a private placement, including strategic investor Sanofi, to fund the Phase 2b SAFEGUARD study and extend operational runway through 2028. In September 2025, SAB Biotherapeutics filed to sell 250 million shares of common stock for holders.

Information regarding demand seasonality for SAB Biotherapeutics, Inc.'s products and services is not available. Demand for its product candidates is primarily driven by clinical trial progress, regulatory approvals, and market adoption rather than typical seasonal patterns.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing human polyclonal immunotherapeutic antibodies for immune system disorders and infectious diseases. They utilize their DiversitAb™ platform with genetically engineered transchromosomic cattle to produce fully human immunoglobulin G antibodies. Their lead product candidate is SAB-142, in Phase 2b clinical trials for Type 1 Diabetes, and they have other candidates like SAB-185 and SAB-176 for COVID-19 and severe influenza, respectively.

SAB Biotherapeutics, Inc. is headquartered in Miami Beach, Florida, with its Research & Development Campus located in Sioux Falls, South Dakota.

SAB Biotherapeutics' brand reputation has been positively influenced by positive topline data from Phase 1 clinical trials for SAB-142 and securing substantial financing, including a $175 million private placement and an $85 million public offering. The establishment of a clinical advisory board also contributes to a positive reputation.

SAB Biotherapeutics, Inc. has a significant level of institutional ownership, with 49 institutional owners and shareholders holding 36,244,448 shares, representing approximately 7.82% of the stock. Major owners include Vivo Capital, LLC, RA Capital Management, L.P., and Commodore Capital LP. Individual insiders hold 2.69% of shares, hedge funds hold 6.26%, VC/PE Firms hold 22.5%, institutions hold 26.8%, and the general public holds 41.6%. The company has experienced substantial dilution in the past year, with total shares outstanding growing by 656.6%.